Clovis Oncology Inc. CLVS shares are gaining ground in Friday’s session. The jump in the shares comes after a company announcement stating that Rubraca significantly improves progression-free survival versus chemotherapy in patients with later-line ovarian cancer associated with a BRCA mutation.
The stock is trading with a market cap of $585 million and a public float of 86.4 million shares.
Clovis Short-Term Chart Analysis: The 5-minute chart above shows the stock ran to $7 in Friday’s premarket session. The stock then consolidated and broke over the $7 level later in the morning. The stock is now trading above this level and it may now be support, as the $7 mark was a previous resistance level.
The stock then ran to a high of $8.44 Friday morning, this level may hold as a potential resistance level.
The stock is trading above both the 200-day moving average (blue) as well as the volume-weighted average price (pink). This gives the stock a short-term bullish sentiment until the price may cross below one of the indicators.
Clovis Daily Chart Analysis: The daily chart on Clovis above shows that the stock looks to be trading around three key price levels.
The first channel it spends a lot of its time in is between the price levels of $5 and $7.50. The $5 mark has held up as a support level many times throughout the last year. This is a hint that it could do the same in the future.
The $7.50 level acts as middle ground: the price below it has previously acted as resistance, and when the price is above $7.50, it likes to act as a support level.
The $10 mark on the chart is where there has been resistance multiple times previously, and it may hold as a resistance again.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
